{"summary": "Author is bullish on Quince Therapeutics (QNCX) based on its LAM-001 inhaled rapamycin program targeting post-lung-transplant BOS and other respiratory conditions, citing promising data, runway to 2028, and a $77.20 one-year target.", "reason": "The author provides a fundamental rationale for the drug's potential based on unmet medical needs and clinical data, despite mentioning personal holdings.", "ideas": [{"symbol": "QNCX", "direction": "long", "thesis": "Author argues Quince Therapeutics' LAM-001 (inhaled rapamycin via mTOR delivery) addresses severe unmet needs in post-lung-transplant BOS, PH-ILD, and SAPH, with data showing reversal of BOS and no existing options for declined lung function. The catalyst is phase data expected throughout 2027 and 2028, with operational runway until 2028. Main risk is clinical trial failure or delay, though the author does not explicitly state this.", "thesis_short": "LAM-001 addresses unmet lung transplant needs", "quote": "They are developing a single drug (LAM-001) and delivery method that will possibly accompany and address unmet needs of those who've undergone lung transplant.", "confidence": 0.7, "sentiment": 0.8, "timeframe": "2027-2028"}], "model": "gemini-3.1-flash-lite", "verified": true, "extraction_model": "deepseek-v4-flash"}
This Reddit post, published September 10, 2026, features u/Unfortunatedude discussing QNCX. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Unfortunatedude · Tickers: QNCX